Top Stories News
Top Stories news
-
News BMS and Gilead Sciences Sign Licensing Agreement
The companies have signed a licensing agreement for the development and commercialization of the REYATAZ and cobicistat fixed-dose combination. -
News Eli Lilly to Withdraw Xigris due to Lack of Efficacy
Eli Lilly has decided to withdraw the product from the market worldwide due to lack of efficacy. -
News LIVE FROM CPHI Worldwide: Robinson Brothers Invests to Increase Capacity
Robinson Brothers Limited has announced details of major investments at its two UK sites, aimed at increasing the companys capacity at the research and development end of the manufacturing scale. -
News LIVE FROM CPHI Worldwide: SAFC Announces the Introduction of CHOZN Cell Line
Designed for use in the production of biopharmaceuticals, the new CHOZN GS-/- cell line is the first commercially available glutamine synthetase (GS) knockout CHO cell line proven to shorten bioproduction times in early development, enabling customers... -
News LIVE FROM CPHI Worldwide: Endeavour Successful in Bid to Develop Carbon Saving Technologies
Endeavour Speciality Chemicals has announced that it has successfully bid for funding under the Carbon Trust sponsored Polymer Fuel Cells Challenge (PFCC) as part of a consortium that also includes ESCs parent company, Robinson Brothe... -
News Live from CPHI Worldwide: SAFC Announces the Completion of SafeBridge Program Assessment
As a widely accepted industry benchmark for handling highly potent pharmaceuticals, the SafeBridge program assessment focuses on four primary areas: management; hazard identification and evaluation; hazard controls; and communication, education and tra... -
News LIVE FROM CPHI: Informex Introduces a Thorough Global Pharma Perspectives Conference
Informex has announced details of the Global Pharma Sourcing Conference to be held December 6-7, 2011 at the Hilton Philadelphia City Avenue in Philadelphia, Pennsylvania. -
News WuXi Pharmaceuticals Acquires Two Chinese Clinical CROs
The two Shanghai-based firms provide services spanning regulatory affairs, Phase IIV clinical trials management, and clinical trial site management, throughout most of China. -
News LIVE FROM CPHI Worldwide: Endeavour Speciality Chemicals Announces New Range of Novel Intermediates
Endeavour Speciality Chemicals announces the launch of new additions to its range of reactive intermediates which includes a set of novel carboxylic acid anhydrides. -
News LIVE FROM CPHI Worldwide: CPHI Worldwide, ICSE, P-MEC and InnoPack Make A Return to Madrid for 2012
UBM Live is excited to announce that CPHI Worldwide will once again be hosted in Madrid, Spain for 2012 running from Oct. 9-11 at the Feria de Madrid. -
News LIVE FROM CPHI Worldwide: Alliance to Manufacture Codeine for UK Market
Aesica and Noramco have formed a partnership that has involved a technical transfer of a process for the manufacture of codeine phosphate from a unique, patented poppy supplied by Noramcos sister company, Tasmanian Alkaloids, allowing for the con... -
News LIVE FROM CPHI Worldwide: New Concept in Cancer Treatment
Latvian Virotherapy Center has in-troduced a treatment for oncological diseases with virotherapy medication Rigvir, an antitumour medication of viral origin. -
News LIVE FROM CPHI Worldwide: Raising the Bar on GMPs Needs to Continue Via Technology
The globalization of the pharmaceutical industry has made it difficult to send inspectors on-site. All the same, 'senior management has to own up to supply chain oversights'. -
News LIVE FROM CPHI Worldwide: By Popular Vote: ICSE Comes to America Joining Established Global Line-up
ICSE USA will join the established global roaster of ICSE events, which focus on the pharmaceutical contract services and outsourcing sectors, and will run from May 22-23, 2012 at the Pennsylvania Convention Centre in Philadelphia. -
News Gilead & GlobeImmune Ink Pact for HBV Therapies
According to the partnership, Gilead will pay GlobeImmune an upfront payment and provide support for GlobeImmune's continued development of its HBV therapeutic vaccine program through Phase 1a clinical trials. -
News Sanofi Appoints David Meeker as CEO of Genzyme
Under Mr. Meekers leadership, Genzyme will incorporate the Rare Disease business and the Multiple Sclerosis franchise. -
News World Bank Finances $359M Health Project in Bangladesh
The programme will strengthen the pharmaceutical distribution and improve health service status in the country. -
News FDA Approves Generic Olanzapine
The FDA has approved generic olanzapine tablets and generic olanzapine orally disintegrating tablets to treat schizophrenia and bipolar disorder. -
News MSD Expands in Singapore with New Investments
Under the agreement, MSD will invest over USD $250 million over the next ten years in site improvements at its manufacturing facilities in Singapore. -
News Syntaxin & Ipsen Ink Botulinum Therapeutic Pact
Syntaxin will be responsible for the discovery of new therapeutic candidates and Ipsen will apply its pharmacological, preclinical and clinical assessments of the discovered compounds. -
News Prasco & Eli Lilly Sign Agreement for Generics
Prasco Laboratories and Eli Lilly have signed a marketing and distribution agreement for two generic products in the U.S. market. -
News Evotec & Apeiron Ink Discovery Pact for Anti-tumor Immune Therapy
Evotec and Apeiron Biologics have entered into a discovery project on the Cbl-b target for an anti-tumor immune therapy. -
News Abbott to Split into Two Pharma Businesses
Abbott plans to separate into two companies, one in diversified medical products and the other in research-based pharmaceuticals. -
News Novartis & SomaLogic Sign Research Deal for Proteomics Technology
SomaLogic has signed a multi-year research agreement with Novartis to use its proteomics technology to accelerate Novartis' drug discovery. -
News Veteran's New Target: A Story from Mark Roberts, Founder of Roberts Chemicals
A 30-year veteran of the fine chemicals industry has launched his own business, with a new model. -
News Servier & Miragen Ink $352M Partnership Deal
Under the partnership, the two companies will advance the research, development and commercialization of three drug candidates. -
News Jubilant Biosys & Norgine Enter into Discovery Agreement
Under the agreement, Jubilant will deliver preclinical candidates and Norgine will have rights to further development and commercialization of treatments in the area of gastrointestinal disease. -
News WHO: Widely Available Treatments Keeping Malaria under Better Control
A WHO report says one-third of the 108 countries, where malaria was endemic, were on course to eradicate the disease within ten years. -
News Roche to Acquire Anadys for $230M
Roche is to acquire Anadys Pharmaceuticals for $230 million in cash to strenthen its HCV portfolio. -
News ICON Appoints Colin Stanley as DOCS President
ICON has named new president of DOCS, the company's global resourcing division. -
News Janssen & BeiGene Sign for Oncology Compounds
The two companies have inked a deal for the clinical development and commercialization of two clinical-stage oncology compounds. -
News WuXi PharmaTech Acquires Abgent for Antibody Reagents
China's CRO WuXi PharmaTech has announced its acquisition of research reagents manufacturer Abgent. -
News Acino Acquires Cephalons Middle East & African Business for 80M
Acino said last week that it agreed to buy the Middle Eastern and African business of Cephalon for 60 million euros in cash and 20 million euros of new shares. -
News CPHI China 2011 Interview: Ms. Li Fang, Manager of Trade Dept., Jiangsu Huanghe Medical Co., Ltd.
The CPHI, ICSE & BioPh China 2011 and P-MEC China 2011 were held in Shanghai from June 21, 2011 to June 23, 2011. During the exhibition, CPHI-Online had an interview with Ms. Li Fang, Manager of Trade Dept., Jiangsu Huanghe Medical Co., Ltd... -
News CPHI China 2011 Interview: Ms. Cindy Zhao, President of J&K Group
The CPHI, ICSE & BioPh China 2011 and P-MEC China 2011 were held in Shanghai from June 21, 2011 to June 23, 2011. During the exhibition, CPHI-Online had an interview with Ms. Cindy Zhao, President of J&K Group. -
News Humana & Pfizer Form Partnership for Health Care Improvement
The partnership will bring researchers and health care experts to study key issues and deliver interventions to reduce inefficiencies in the management of chronic conditions. -
News EU Approves Teva & Cephalon Acquisition
With this approval from the European Commission, the two companies have now obtained all regulatory approvals required to close the transaction. -
News Pfizer & deCODE Ink Pact for Sequence Variants Discovery
The two companies will jointly analyze patient genomes to search for sequence variants that would be useful for understanding drug targets and discovering novel drug targets. -
News Canada's Paladin Labs Acquires Labopharm
Canadian pharmaceutical firm Paladin Labs completes the acquisition of drug developer Labopharm. The acquisition will help them build upon their existing operational capabilities. -
News GlycoMimetics & Pfizer Ink Licensing Deal
The potential value of the agreement for GlycoMimetics is approximately $340 million, including an upfront payment as well as development, regulatory and commercial milestones. -
News BMS Foundation Collaborates with WHO Stop TB Department
The collaboration is established for a two-year pilot initiative to strengthen community based prevention, care and control of tuberculosis including co-infection with HIV in five African countries. -
News EMA Supports World Arthritis Day
World Arthritis Day is held each year on 12 October. To date, 18 medicines for patients with rheumatoid arthritis have been authorised on the recommendation of the Agency. -
News US Signs MoU with Russia to Improve Medicine Quality
The two countries will cooperate in several fields to improve the quality of medicines in their respective countries. -
News German Biotech Firm Apceth Extending Top Management
German biotech company Apceth has extended its top management after Prof. Ralf Huss, previously Global Head of the Therapeutic Cell Initiative at Roche, joined the management board of apceth on October 1st. -
News AstraZeneca Plans New $200M Manufacturing Facility in China
The new site will produce both intravenous and oral solid medicines and will enable AstraZeneca to meet the growing demand for its products in the country. -
News AstraZeneca to Cut 400 Jobs in the US
The decision of the job cuts comes as AstraZeneca faces increasing pressure from generics as the company approaches a 2016 patent cliff. -
News Exonhit Enters Into Research Agreement With Pfizer
French biotech company Exonhit will work with Pfizer for the identification of new Alzheimer's disease biomarkers. -
News Sanofi & Genzyme Announce TEMSO Data
Sanofi and its subsidiary Genzyme have announced the results of the pivotal Phase III TEMSO study with investigational once-daily oral medication teriflunomide. -
News Pfizer to Launch Manufacturing Plant in Saudi Arabia
Pfizer plans to build a major new pharmaceutical manufacturing and packaging plant in Saudi Arabia. -
News FDA Investment to Support NIPTE's Drug Programmes
The investment up to $35 million over the next five years will support programmes to rectify drug development and manufacturing problems to improve drug manufacturing standards in the US. -
News UK Promises Better Access to Drugs for Patients with Rare Diseases
The UK Department of Health will commission expert assessments of the evidence on the use of off-label medicines for patients with rare diseases. -
News India & Russia Sign Collaboration MoU for Pharma Research
The collaboration will strengthen the relation between India and Russia at the educational level along with raising the competitiveness of the industry by stimulating the production of innovative medicines. -
News PPD to Be Acquied by US Private Equity in $3.9B Deal
Pharmaceutical Product Development is to be bought by US private equity firms The Carlyle Group and Hellman & Friedman for US$3.9bn in cash. -
News Pfizer Signs Licensing Agreement with Puma
Puma Biotechnology will assume sole responsibility for global development and commercialization of neratinib which is being studied for the treatment of cancer. -
News Merck Chairman to Retire in December
Merck & Co.'s former CEO, Richard T. Clark, is retiring as chairman effective December 1st. -
News Evotec Forms Drug Discovery Collaboration with UCB
Evotec AG has entered into a multi-target drug discovery collaboration with UCB in the field of immunology. -
News Takeda Completes Acquisition of Nycomed
Osaka-based Takeda hopes the addition of the Swiss firm will boost Takeda's sales by approximately 30% and move the company to 12th in the pharmaceutical sales table. -
News Rexahn Completes Patient Recruitment in Cancer Drug Trial
Rexahn Pharmaceuticals has completed enrollment for a Phase II clinical trial of its experimental cancer drug Archexin. -
News Evotec Takes over Full Ownership of JV in India
Evotec has agreed to acquire the remaining 30% of its Joint Venture with DIL Ltd., India for $2.3 million. -
News Japan's Santen to Acquire French Novagali
Japanese drugmaker Santen Pharmaceutical said on Wednesday it has agreed to buy 50.55 percent of French biopharma Novagali. -
News Helsinn Healthcare & Riemser Arzneimittel Expand Licensing Agreement
Helsinn Healthcare and Riemser Arzneimittel signed an agreement to grant marketing rights in Germany to Riemser for a next-generation treatment in development for the prevention of chemotherapy-induced nausea and vomiting. -
News NIBRT Collaborates with GE Healthcare for Novel Analytical Platforms
The collaboration aims to develop new, robust and reproducible biochemical assays for the analysis of the biological activity of therapeutic monoclonal antibodies. -
News AmerisourceBergen to Acquire TheraCom for $250M
Pharmaceutical wholesaler AmerisourceBergen has agreed to buy TheraCom, a subsidiary of CVS Caremark, for $250 million. -
News Biotie Therapies to Acquire Newron for 45M
Finnish biotech Biotie Therapies will purchase Italian biopharmaceutical firm Newron Pharmaceuticals for 45m. -
News Lonza & Mesoblast Ink Manufacturing Pact for Stem Cell Products
Lonza has entered into a strategic alliance with Australia-based Mesoblast for the production of Mesoblast's adult stem cell therapies. -
News PCCA Urges Member Pharmacists to Offer Solutions for Drug Shortages
PCCA President urges member pharmacists to continue their efforts to reduce the growing issue of drug shortages. -
News Merck Opens R&D Facility in Ireland
Six drugs are currently in development at the facility, including Merck's candidate drug for the treatment of hepatitis C and a dual high cholesterol/type II diabetes medication. -
News SK Biopharmaceuticals with Mayo Clinic for Sclerosis Drug Development
The South Korean biotech forms a partnership with Mayo Clinic to focus on research into chemical compounds that target a type of protein known as TDP-43. -
News Loxbridge with Nobel Prize Winner to Combat Superbugs
Loxbridge Research signed a joint venture agreement to form Altermune Technologies to develop new therapeutics targeting combat resistant pathogens. -
News BMS & Ambrx Form Collaboration in Two Therapeutic Areas
New York-based Bristol-Myers Squibb has inked an agreement with Ambrx to research, develop and commercialize biologics based on Ambrx's research surrounding the Fibroblast Growth Factor 21 protein and the Relaxin hormone. -
News India's Drug Regulators to Send Delegation to Inspect Manufacturing Sites in China
This will be the second auditing and inspection of manufacturing facilities in China. The CDSCO delegation inspected five manufacturing sites in China in May which have been found to be in good condition. -
News Lilly Invests $30M in Partnership to Address Chronic Diseases
The partnership will initially focus on diabetes - a core business area in which Lilly has deep expertise. -
News BMS Inks Cancer Drug Pact with Japanese Pharma
Ono Pharmaceutical, based in Osaka, has granted BMS exclusive rights to develop and sell the potential cancer treatment worldwide except in Japan, Korea and Taiwan. -
News Sanofi Pasteur Announces R&D Collaboration for Skin Disease Treatment
Sanofi Pasteur has announced a research and development collaboration with the University of California on an immunological approach to acne prevention and treatment. -
News India Forms 12 New Drug Advisory Committees
The 12 New Drug Advisory Committees will advise the Drugs Controller General of India in matters for review of applications of new drugs and clinical trials. -
News EMA Supports World Alzheimer's Day
To date, a total 11 medicines for use in patients with Alzheimer's disease have been authorised in the EU on the recommendation of the EMA. -
News Roche Partially Halts Drug Supplies to Greek Hospitals
Some state-funded hospitals in Italy and Portugal are also failing to pay their bills, and Roche has warned that drug deliveries may also be halted in Spain for the same reason. -
News Teva & Cocrystal Discovery Ink Antiviral Pact
Teva will initially invest $7.5 million in CDI for the development of an antiviral drug targeting the polymerase enzyme of the hepatitis C virus. -
News Chesapeake Acquires Cortegra to Expand US Pharma Market
Chesapeake Pharmaceutical and Healthcare Packaging has agreed to buy Cortegra Group, a US-based contract producer of packaging and leaflets. -
News GlaxoSmithKline Forms Partnership with McLaren
GSK has formed a five-year partnership with Formula 1 team McLaren to drive its manufacturing operations and research. -
News Novo Nordisk Launches Programme in India for Children with Diabetes
The programme, known as Changing Diabetes in Children, aims to reach over 2500 kids with type I diabetes from underprivileged families over the next two years. -
News Genentech Submits NDA for Skin Cancer Drug Vismodegib
Biotechnology firm Genentech has submitted a NDA for vismodegib to the FDA for the treatment of advanced basal cell carcinoma. -
News Spaulding Clinical & Frontage Labs Form Partnership for Clinical Development
Frontage will provide bioanalytical method development and sample processing, formulation development and clinical trial product supplies for Spaulding. -
News Debiopharm Signs Licence Agreement with Ascenta for Cancer Drug
The two companies have signed an exclusive licence agreement for the development and commercialization of a tumours treatment currently in Phase I development. -
News India's Aurobindo Forms JV with OJSC Diod for Russian Market
The joint venture, named Aurospharma, will include a manufacturing facility near Moscow, due to be completed in 2013. -
News UK-based Pharma Firms Ink Deal for Cancer Drug Programme
Under the agreement, Ark will provide manufacturing and related services to support the development of PsiOxus ColoAd1 programme for the treatment of colorectal cancer. -
News Sucampo & Numab Enter into Discovery Collaboration for Antibodies
Sucampo Pharmaceuticals signs an R&D collaboration deal with Numab for the discovery of antibodies using the latter's high-affinity antibody technology. -
News Cuba Distributes First Lung Cancer Vax in Hospitals without Charge
Cuban medical authorities have launched the distribution of CimaVax-EGF, the world's first lung cancer vaccine, in Cuban hospitals free of charge. -
News Alchemia Starts Phase II Trial in Small Cell Lung Cancer
This study will examine the effectiveness of HA-Irinotecan, which utilizes Alchemia's technology to target the anti-cancer drug irinotecan to the tumor. -
News HCN2 Gene Gives Hope to Treat Chronic Pain
Researchers has identified a gene responsible for chronic back pain. -
News Lung Disease Therapy Esbriet to be Launched in Germany
Esbriet will be commercially available in Europe for the first time since it was approved by the European Commission in adults for the treatment of mild to moderate idiopathic pulmonary fibrosis. -
News BMS Completes Acquisition of Amira
Bristol-Myers Squibb has completed its previously announced acquisition of small-molecule pharmaceutical company Amira Pharmaceuticals. -
News HHS Awards $94M to GSK for New Antibiotic Development
GlaxoSmithKline will receive $94m from the US Department of Health and Human Services for a promising new antibiotic research and testing. -
News Germany to Invest Billions for Healthcare Research
The new programme will provide a boost to bringing research results rapidly to market, according to Germany Trade & Invest. -
News BioLineRx Signs License Deal for Pain Treatment BL-7050
BioLineRx announced yesterday its worldwide, exclusive license agreement with Ramot at Tel Aviv University for a neuropathic and inflammatory pain treatment. -
News Merck Serono & F-Star Collaborate for Novel Targeted Biologics
Austria's F-Starfor announced yesterday the agreement with Merck Serono for the discovery of new antibody-derived therapeutics against inflammatory disease targets. -
News Evotec & Roche Ink Alzheimer's Pact
Evotec and Roche have teamed up to develop and commercialize MAO-B inhibitor of Evotec for the patients with Alzheimer's disease. -
News WHO & FIP Sign Landmark Initiative for Tuberculosis Care Improvement
The WHO and the FIP signed a joint statement seeking to involve pharmacists in tuberculosis care and control. -
News Addex Regains Parkinson's Programme Rights from Merck
Merck originally licensed the rights to the programme in 2007 in a deal potentially worth as much as $170.5m. -
News Pfizer & Sanofi Sign Deal for Generic Lipitor
Pfizer has granted Sanofi a licence to manufacture a generic version of the product and launch it after Lipitor's patent expires in the country on 7 May 2012. -
News Oxford Pharmascience Licenses Colonic Drug Delivery Technology
Oxford Pharmascience partners with University of London to have the option to license and research an advanced colonic drug delivery technology. -
News AstraZeneca's Crestor Fails to Best Lipitor in Study
According to trial results announced recently, Crestor, the statin drug from AstraZeneca, failed to best Lipitor at clearing clogged arteries. -
News Pfizer Inks Lease Deal with MIT for New Research Center
The new research site will be Pfizers Cardiovascular, Metabolic and Endocrine Disease (CVMED) and Neuroscience Research Units. -
News Pfizer & Dr Reddy's Settle Lipitor Patent Lawsuit
Pfizer, the worlds largest drugmaker, settles a lawsuit with the Indian generic-drug maker Dr. Reddys Laboratories over the cholesterol treatment Lipitor. -
News Teva Inks Cancer Pact with UK's Sinclair IS
Teva has signed an agreement with Sinclair IS to gain exclusive commercialisation rights of oncology medication Episil in Germany, Spain, Poland, Switzerland and the Czech Republic. -
News Bayer Healthcare to Acquire Pathway Medical Technologies
Bayer HealthCare's affiliate, MEDRAD, Inc. acquires Pathway Medical Technologies to strengthen its MEDRAD Interventional business by expanding its presence in the field of vascular intervention technologies. -
News OXiGENE to Restructure to Focus Clinical Resources on Earlier Stage Development Programs
Biopharmaceutical firm OXiGENE, Inc. decides to restructure in an to focus resources on its most promising early-stage clinical programs. -
News Pfizer Extends Tender Offer to Acquire Icagen
Pfizer's subsidiary, Eclipse Acquisition Corp. , has extended the expiration date of its tender offer for Icagen. -
News BMS Chooses ICON as Provider for Clinical Services
Under the agreement, ICON will become a preferred provider for full-service clinical pharmacology and exploratory clinical studies. -
News Valeant to Acquire Afexa for $76M
Valeant Pharmaceuticals will acquire cold and flu medicine maker Afexa Life Sciences for approximately $76 million. -
News Survey: US Hospitals Turn to Gray-market Vendors as Drug Shortage Continues
The study of 549 hospitals indicates that 52% of respondents purchased one or more pharmaceutical products from back-door suppliers during the past two years. -
News Adimab Forms Discovery Collaborations with Biogen & Novo Nordisk for Antibodies
Adimab will receive upfront payments and preclinical milestones from both companies, and is eligible to receive clinical development milestones and royalties on sales. -
News Merck & Zymeworks Ink $187M Deal for Bispecific Antibody
Under terms of the deal, Zymeworks will receive an up-front fee and could earn research, development, and regulatory milestones of up to $187 million. -
News India's Piramal to Invest $1.5B in Overseas Pharma Business
India's Piramal plans to invest at least $1.5 billion in biotech acquisitions and Big Pharma joint ventures to expand its overseas business. -
News Eisai to Expand Operations in Canada
Eisai will establish its Canadian headquarters in Mississauga, Ontario and the expansion into Ontario will increase access to a variety of therapies and medications. -
News UK Starts Probe into AstraZenca's Drug Mix-up
British health authorities warned that packages of an over-the-counter painkiller were found to contain antipsychotic drugs. -
News Cresset & Redx Pharma Form Drug Discovery Collaboration
Two UK firms have agreed to collaborate on drug discovery. -
News CPHI China 2011 Interview: Ms. Yu Lingmin, Manager of NO.1 Pharmaceutical Dept, A.H.A International CO., LTD
The CPHI, ICSE & BioPh China 2011 and P-MEC China 2011 were held in Shanghai from June 21, 2011 to June 23, 2011. During the exhibition, CPHI-Online had an interview with Ms. Yu Lingmin, Manager of NO.1 Pharmaceutical Dept, A.H.A Internatio... -
News Sanofi to Buy India's Universal Medicare
Sanofi announced to acquire India's nutraceuticals company Universal Medicare. The transaction is expected to close in the fourth quarter of this year. -
News Scotland's Research Organisations Collaborate for Drug Formulations Development
The combination of two research organisations will enable them to offer integrated pharmaceutical and clinical development solutions.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance